Renibus Therapeutics Announces $47 Million Financing To Advance Lead Program Rbt-1 Through Pivotal Phase 3 Trial

Jul 18, 2023•over 2 years ago

Amount Raised

$47 Million

SouthlakeBiopharmaTherapeuticsHealth CareMedicalBiotechnology

Description

Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced raising $47 million from the initial closings of a Series B financing.

Company Information

Company

Renibus Therapeutics

Location

Southlake, Texas, United States

About

Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic surgery. Other programs include RBT-2 for slowing CKD progression, RBT-3 for preventing cisplatin-induced nephrotoxicity, and RBT-9, an anti-inflammatory compound that showed promise in reducing hospital stays in COVID-19 patients.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Renibus Therapeutics Announces $47 Million Financing To Advance Lead Program Rbt-1 Through Pivotal Phase 3 Trial

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information